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the control. Collagen-induced whole blood plateletAbstract
aggregation increased drastically for the peak con-
centration-treated group, while adenosine 59-di-Cyclosporin A plays an important role in preventing
phosphate-induced platelet aggregation did notrejection in allograft transplant recipients. How-
reach statistical significance. Finally, in vitro plate-ever, the therapeutic use of cyclosporin A is associ-
let thromboxane A2 generation increased inated with increased incidence of thromboembolic
cyclosporin A concentrations when platelets werecomplications and drug-related hypertension. In
stimulated with either collagen or adenosine 59-order to study the mechanisms by which cyclo-
diphosphate. In conclusion, both tested cyclosporinsporin A induces these abnormal pathophysiologi-
A concentrations induced important changes incal situations, we have assessed the platelet seroto-
platelet serotonin and thromboxane content andnin contents and whole blood platelet aggregation
aggregation, factors which may play a decisive rolein control rats as well as in rats treated (orally)
in the development and/or maintenance of hyper-with 30 and 5 mg/kg/day of cyclosporin A, after 2
tension and thrombotic complications.  1999and 7 weeks of treatment. These doses correspond
Elsevier Science Ltd. All rights reserved.respectively to CsA “peak” and “trough” concen-
trations achieved in human blood in clinical prac-
Key Words: Cyclosporin A; Hypertension; Thromboem-tice (immediately following an intake of a daily
bolic complications; Serotonin; Aggregationdose of CsA and when the blood concentration
stabilizes, respectively). Both trough and peak
Cyclosporin A (CsA) is a potent and clini-doses caused an increase in blood pressure after 2 cally relevant immunosuppressive agentand 7 weeks. Platelet serotonin content decreased and is widely used in organ transplanta-in the cyclosporin-treated groups, in contrast with
tion [1,2] and also in the treatment of autoimmune
diseases [3]. However, despite its effectiveness,
CsA therapy has been associated with drug-relatedAbbreviations: CsA, cyclosporin A; 5-HT, 5-hydroxytryptamine;
TXA2, thromboxane A2; PRP, platelet-rich plasma; ADP, adeno- hypertension [4–7] and increased risk of thrombo-
sine 59-diphosphate; PPP, platelet-poor plasma; TXB2, thrombox- embolic complications [8–10], which may be partly
ane B2; SBP, systolic blood pressure; DBP, diastolic blood pres-
due to the direct effects of CsA on platelets [11–14].sure; MBP, mean blood pressure.
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naturally found vasoconstrictors, such as throm- blood concentration stabilizes (“trough”). These
concentrations also corresponded to the 30 and 5boxanes and endoperoxides. Many studies have
mg/kg/day of CsA administered to the rats.reported cyclosporin A-induced changes in the
thromboxane/endoperoxides balance [13,15,16], in
enhanced hemostasis and reduced thrombolysis 1.2. Collecting the Blood
[17,18], in increased platelet aggregability [12– and Preparing the Platelets
14,19], as well as in altered peripheral serotonergic
mechanisms [14,20–22]. Serotonin (5-hydroxytryp- Following intraperitoneal ketamine anesthesia,
blood was withdrawn by venipuncture from thetamine, 5-HT), mainly present in platelets, has
jugular vein and added to an anticoagulant solutionbeen linked with thrombotic complication and in-
(0.1 mL/mL blood) containing (in mmol/L) citriccrease in blood pressure [23,24]. When activated,
acid (71), sodium citrate (85), and d-glucose (111).platelets adhere and aggregate to the damaged en-
The blood was centrifuged (1603g for 10 minutesdothelium, releasing (among other compounds) se-
at 208C) to obtain platelet-rich plasma (PRP) androtonin and thromboxane A2 (TXA2), which may
the platelets were then recovered by recentrifuga-act as vasoconstrictors and also extend aggregation
tion at 7303g for 10 minutes at 208C.to other agonists, thus promoting thrombus for-
mation.
1.3. Platelet Serotonin ContentsTherefore, the purpose of this study was to deter-
mine the effects of CsA on the peripheral seroton-
The platelet pellet was resuspended in 1 mL of aergic system, platelet aggregation, and TXA2 gen-
buffer solution (pH 7.4) containing (in mmol/L):eration.
NaCl (145), KCl (5), MgSO4 (1), CaCl2 (1), d-glu-
cose (10), and 120 mL of perchloric acid (70%) was
added. Following 15 minutes at ice temperature,1. Materials and Methods
the suspension was finally centrifuged at 7303g for
10 minutes at 208C and the supernatant containing1.1. Animals and Diets
the released serotonin was collected for quantifica-
tion. Platelet 5-HT was determined by high pres-Male Wistar rats (Charles River Laboratories Inc.,
sure liquid chromatography with electrochemicalBarcelona, Spain), ,300 g, were maintained in an
detection. The chromatographic system consistedair-conditioned room, subjected to 12-hour dark/ of a Gilson Applied Chromatographic System
light cycles and given standard laboratory rat chow (Middleton, WI, USA) with a 305 model pump and
and free access to tap water. Animal experiments a 231 injection valve model, with a 50-mL loop. A
were conducted according to the European Con- Biophase ODS Reverse Phase 18 analytical column
vention on Animal Care, and the whole research (25034.6, [55 m, Bioanalytical Systems Inc., West
project was approved by the Portuguese National Lafayette, IN, USA) was used and separation was
Foundation for Science and Technology. The rats made possible by using an isocratic solvent system
were divided into three groups: one group received consisting of an acetate-citrate buffer (sodium ace-
orange juice only (control) and the others received tate 0.1 mol/L, citric acid 0.1 mol/L) containing
5 and 30 mg/kg/day of CsA (Sandimmun Neoral, sodium octane sulphonate (0.5 mmol/L ), etylene-
Sandoz Pharma, Basel, Switzerland) dissolved in dinitrilo-tetraacetic acid (0.15 mmol/L), dibuty-
orange juice for 7 weeks. Blood pressure values lamin (1 mmol/L), and 10% methanol. A flow rate
(systolic, diastolic, and mean) were measured using of 1 mL/minute was maintained and detection of
a tail-cuff sphygmomanometer. Thromboxane in the chromatographed serotonin was achieved by
vitro studies were carried out through the incuba- using a 141 Gilson electrochemical detector model
tion of platelets with CsA (dissolved in dimethyl (650 mV).
sulfoxide) at 0.1 and 1.0 mmol/L concentrations.
These concentrations were calculated to match the 1.4. Whole Blood Platelet Aggregation
real blood concentrations of patients taking CsA:
1.0 mmol/L immediately after an intake of a daily Whole blood platelet aggregation was monitored
by measuring electric impedance, using a Chrono-dose of CsA (“peak”) and 0.1 mmol/L, when the
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log aggregometer (Chrono Log, Havertown, PA, the percentage of iodinated TXB2 bound to a pro-
tein precipitate, and read from a standard curve.USA). This technique is based on the detection of
All assays were performed in duplicate.changes in electrical resistance between two elec-
trodes submerged in the sample. Fresh heparinized
(0.5 mL) whole blood and 0.9% NaCl (0.5 mL) 1.6. Chemicals
were mixed using a magnetic stirrer and allowed
to balance at 378C for 5 minutes before adding the Cyclosporin A (Sandimmun Neoral) was supplied
by Novartis Farma, Lisbon, Portugal. ADP andagonists adenosine 59-diphosphate (1.0 mmol/L)
collagen were obtained at Chrono-log Corp., Hav-and collagen (5 mg/mL). Platelet count and mean
ertown, PA, USA. A thromboxane B2 radioimmu-platelet volume were measured with a Coulter
noassay kit was purchased from R&D Systems,counter.
Abingdon, UK. All the other chemicals were of the
highest analytical grade and were obtained from1.5. Platelet Thromboxane B2 Generation
Sigma, St. Louis, MO, USA.
The blood was collected into plastic syringes con-
1.7. Statistical Analysistaining 1 vol of 3.8% trisodium citrate for every 9
vol of blood. Aliquots were incubated for 3 hours
Data are expressed as means6SEM of n experi-at 378C with either solvent (control) or CsA in
ments. Groups were tested for differences by usingfinal concentrations of 0.1 and 1.0 mmol/L. The
ANOVA and Student’s t test.remaining blood was divided into aliquots con-
taining CsA or solvent to measure the potentially
maximum amount of releasable thromboxane. 2. Results
After incubation, whole blood samples were centri-
fuged as described previously to obtain PRP and 2.1. Blood Pressures
platelet-poor plasma (PPP). Platelets were counted
using the Coulter counter (350,000650,000 plate- Systolic blood pressure (SBP), diastolic blood pres-
lets/mL). They were subsequently activated with sure (DBP), and mean blood pressure (MBP) mea-
1.0 mmol/L of ADP and 5 mg/mL of collagen. Fol- surements were performed in all rats of the control
lowing aggregation, the supernatants were assessed and CsA-treated groups, before (0 week) and 2
to determine the amount of thromboxane B2 and 7 weeks after initiating the CsA administra-
[(TXB2) the stable end product of TXA2] gener- tions. The DBP increased significantly after 2 and
ated. Briefly, the contents of the cuvette was trans- 7 weeks of treatment in the CsA-treated groups,
ferred to a microcentrifuge tube containing 10 especially in the CsA(5) group (week 2: 9661,
mmol/L etylene-dinitrilo-tetraacetic acid and 10 11962, and 11461 mm Hg; week 7: 10361, 11462,
mmol/L indomethacin and centrifuged at 12,0003g and 11261 mm Hg) (p,0.05) for control, CsA(5),
for 4 minutes. The resulting supernatant was frozen and CsA(30), respectively (Table 1). Similar
at 2708C to later analyse the TXB2. A sample of changes were recorded for the SBP. After 2 weeks,
PRP merely spun without the addition of ADP or an increase in the SBP was registered in the CsA-
collagen was also assessed to serve as a control for treated groups (19062 mm Hg for CsA5 and 17961
any spontaneous TXB2 generation. To determine mm Hg for CsA30), contrasting with the control
the total amount of releasable TXB2 in both the (16361 mm Hg; p,0.05). In week 7, the figures
presence and absence of CsA, 20 mmol/L calcium were approximately the same as those in week 2
chloride was added to the initial aliquots, and the (Table 1). The MBP also increased for the two
citrated blood was allowed to clot at 378C for 30 CsA groups after 2 and 7 weeks, compared with
minutes. Following centrifugation, the serum was the control (Table 1).
separated and stored at 2708C until analyzed for
the total amount of TXB2 generated. The amount 2.2. Platelet Serotonin Contents
of TXB2 released in both PRP and serum prepara-
tions was assessed by radioimmunoassay (R&D The platelet serotonin measurements in the control
and CsA-treated groups (5 and 30 mg/kg/day) wereSystems, Abingdon, UK), measured by calculating
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Table 1. The effect of CsA on blood pressure after 2 and 7 weeks of treatment
Blood pressure Treatment Control Treated with Treated with
(mm Hg) (weeks) (untreated) CsA(5) CsA(30)
SBP 0 16561 16563 16161
2 16361 19062* 17961*
7 16461 18963* 17861*
DBP 0 10062 8965 10062
2 9661 11962* 11461*
7 10361 11462* 11261*
MBP 0 12162 11264 12061
2 11861 14262* 13661*
7 12063 13664* 13461*
Data are expressed as means6SEM of 20 separate values. SBP, systolic blood pressure; DBP, diastolic blood pressure;
MBP, mean blood pressure. CsA(5), cyclosporin A (5 mg/kg/day); CsA(30), cyclosporin A (30 mg/kg/day).
*p,0.05 between the control group and each of CsA-treated group.
performed in week 0 (before starting the adminis- 2.3. Whole Blood Platelet Aggregation
trations) and in weeks 2 and 7. In week 0, the
We tested the effects of cyclosporin A on wholeplatelet 5-HT concentration of the control group
blood platelet aggregation induced by collagen (5was similar to that of the CsA-treated groups (Fig-
mg/mL) and ADP (1.0 mmol/L), after 2 and 7 weeksure 1). In week 2, there was a decrease in the
of treatment. Before the start of CsA administra-platelet serotonin contents of the CsA-treated
tions, similar values were obtained for platelet ag-groups in contrasting to the control group [in ng/
gregation in the control and the CsA-treatedmL: 1105641 for control, 899625 for CsA(5) and
groups. Thus, only one mean is presented in week698621 for CsA(30); p,0.05]. Similar results were
0, which expresses values from the three groupsobtained in week 7: 999624 for control, 877617 for
(Table 2). After 2 weeks of treatment, no statisti-CsA(5), and 672619 ng/mL for CsA(30), p,0.05
cally significant increases in ADP-induced whole
(Figure 1). blood platelet aggregation were identified. In the
CsA-treated groups, values for collagen-induced
aggregation were significantly increased after the
second week of treatment compared to those of
the control group. These changes were most notice-
able in the group that received 30 mg/kg/day of
CsA. The results after 7 weeks of administration
more or less confirmed those obtained after the
second week (Table 2).
2.4. Platelet Thromboxane B2 Generation
Baseline supernatant TXB2 levels were 251.867.9
ng/mL in control platelets compared to 315.668.3
ng/mL and 304.568.1 ng/mL (p,0.05) in CsA-
Fig. 1. The effect of CsA on rat platelet serotonin contents treated platelets, trough and peak, respectively
after 2 and 7 weeks of treatment. Data are expressed as (Figure 2). In ADP-stimulated platelets, TXB2 re-means6SEM of 10 separate values: CsA(5), cyclosporin lease increased in the 0.1 and 1.0 mmol/L CsA-A (5 mg/kg/day); CsA(30), cyclosporin A (30 mg/kg/day).
treated platelets compared to control. When plate-An asterisk indicates the difference (p,0.05) between the
control group and each of CsA-treated group. lets were stimulated with collagen, there was a sig-
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Table 2. The effects of CsA on whole blood platelet aggregation and platelet count and volume after 2
and 7 weeks of treatment
Aggregation (Ohms)Treatment Rat Platelet
(week) group ADP (1.0 mmol/L) Collagen (5 mg/mL) (3109/L) MPV (fL)
0 16.060.5 10.660.6 611616 5.360.1
2 Control 16.160.5 10.160.4 631631 5.460.2
CsA(5) 17.161.1 13.461.0* 611618 5.660.1
CsA(30) 15.960.7 16.561.1* 609627 5.660.2
7 Control 15.060.6 12.061.5 598632 5.460.1
CsA(5) 15.860.9 13.360.8* 573624 5.560.2
CsA(30) 15.460.5 17.360.9* 603621 5.660.1
Data are expressed as means6SEM of 10 separate values. ADP, adenosine-59-diphosphate; MPV, mean platelet volume; CsA(5), cyclosporin
A (5 mg/kg/day); CsA(30), cyclosporin A (30 mg/kg/day).
*p,0.05 between the control group and each of CsA-treated group.
nificant increase in TXB2 release for both CsA three groups of rats at any stage of the study
(Table 2).concentrations compared to control (Figure 2).
Serum TXB2 levels that were generated in control
and CsA-treated whole blood allowed to clot were
321610.4 ng/mL for control and 342612.3 and 3. Discussion
29769.4 ng/mL (p,0.05) for 0.1 and 1.0 mmol/L
The present investigation was aimed at studyingof CsA (not shown).
the peripheral serotonergic system, platelet aggre-
gation, and blood pressure of rats treated with2.5. Platelet Count and Mean Platelet Volume
cyclosporin A at 5 and 30 mg/kg/day after 2 and 7
weeks of administration. These CsA concentra-As control parameters, we also counted the plate-
tions were chosen because they corresponded tolets and measured the mean platelet volume. No
different stages of the CsA absorption in clinicalsignificant differences were obtained between the
practice. Therefore, 30 mg/kg/day of CsA adminis-
tered to a rat represents the peak value of CsA
achieved in human blood immediately following
an intake of a daily dose, whereas 5 mg/kg/day in
the rat corresponds to the trough concentration
after blood concentration stabilization. The choice
of the 2- and 7-week time periods was based on
the fact that 2 weeks could correspond to an acute
situation and 7 weeks to a chronic situation. The
blood pressures rose significantly in the rats of
the CsA-treated groups (5 and 30 mg/kg/day) after
both 2 and 7 weeks of administration. So, as we
initially expected, both trough and peak concentra-
tions were really effective in increasing blood pres-
sures.
Serotonin, due to its proaggregatory and alsoFig. 2. In vitro effect of CsA on rat platelet TXB2 genera-
tion. Data are expressed as means6SEM of five separate vasoconstrictor properties, may play an important
values (performed in duplicate): CsA (0.1), cyclosporin A role in the thromboembolic and hypertensive ef-
(0.1 mmol/L); CsA (1.0), cyclosporin A (1.0 mmol/L). An
fects of CsA. Platelets are the main storage site ofasterisk indicates the difference (p,0.05) between control
5-HT and changes in their contents may reflectplatelets and platelets treated with each of CsA concen-
tration. important physiological alterations, especially re-
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garding thrombotic and hypertensive effects. In maximal platelet activation after 2 hours but re-
verted to normal after 4 hours, thus suggesting thatthis study we have identified a decrease in platelet
sustained exposure is needed to activate platelets5-HT contents in both CsA-treated groups. Similar
consistently. In fact, they did not observe the sameresults were already obtained by others in a CsA
reversion in patients taking cyclosporin A: platelettreatment patient situation [14] and also in other
activation at trough levels increased, but under-hypertensive situations [25–27]. Low platelet sero-
went a further increase at peak concentrations.tonin concentration may be due to decreased up-
Their results are in agreement with those obtainedtake or increased release, as was documented in
by Vanrenterghem et al. [8], who point out a posi-other studies, both in CsA [14] and non-CsA in-
tive link between CsA levels and enhanced aggre-duced hypertension [25,28]. If serotonin is abnor-
gation. Our results confirmed the nonsignificantmally released by platelets, an increase in the
increases in ADP-induced aggregation and the sig-plasma concentration of this amine could be ex-
nificant increases in aggregatory response to colla-pected and consequently an increased deposition
gen, already obtained by Malyszko et al. [14] andon collagen fibres of the vessel wall, thus promoting
Taylor et al. [32], and the positive link betweendirect vasoconstriction and platelet aggregation
CsA levels (trough and peak) and increases in col-amplification. In agreement with our hypothesis,
lagen-induced aggregation, extending the resultsseveral papers have already reported that the in-
obtained by Grace et al. [12] and Vanrenterghemcrease in whole blood and plasma 5-HT is intensi-
et al. [8].fied during CsA treatment [14,20,22] and in other
Confirming a platelet state of hyperactivity, wehypertensive situations as well [25,27]. On the other
have obtained significant increases in platelethand, cyclosporin A induces endothelial damage TXA2 release at baseline and by platelet stimula-[29,30] that may contribute to increased vasocon- tion with both ADP and collagen. Peak-trough dif-
strictor response and platelet aggregation [31]. ferences were observed by collagen stimulation in
Thus, considering the above-mentioned infor- agreement with aggregation results and also with
mation, an increase in platelet aggregation with platelet 5-HT content results, thus suggesting a pro-
CsA treatment is expected. In our study, whole portional relationship between CsA levels, throm-
blood platelet aggregation induced by collagen, but boxane, and 5-HT release and platelet aggregation.
not by ADP, was increased in the rats of the CsA- In conclusion, this study points out that both
treated groups when compared with control, as also CsA concentrations that we tested influence blood
was shown in other studies carried out by other pressure, platelet serotonin, and thromboxane con-
investigators. In kidney transplant recipients, Ma- tents and aggregation. Increased platelet aggrega-
lyszko et al. [14] found that CsA increased colla- tion, together with increased proaggregating and
gen- and ADP-induced whole blood and PRP ag- vasoconstricting agents concentration (at least
gregation when compared with healthy volunteers. 5-HT and TXA2), near a damaged and/or dysfunc-
However, by ADP stimulation whole blood and tional vessel wall might provide the conditions to
PRP aggregations were not statistically significant, intensify vasoconstriction and platelet thrombus
formation, which may certainly contribute to theas was also confirmed by Taylor et al. [32]. Mysli-
development and/or maintenance of hypertensionwiec et al. [21] indicated a rise in ADP-induced
and increased risk of thromboembolic complica-and 5-HT-augmented platelet aggregation in ure-
tions.mic rats, injected subcutaneously with 5 mg/kg/day
of CsA after 2 and 4 weeks of administration, but
The kind collaboration of Novartis Farma, Lisbon, Portugal, yieldeddid not find statistical significance in nonuremic the cyclosporin A (Sandimmun Neoralt). Also our special thanks
rats treated with CsA when compared with the to the Fundac¸a˜o para a Cieˆncia e Tecnologia, for supporting this
project financially (PRAXIS/PSAU/C/SAU/57/96).control. Grace et al. [12] demonstrated that platelet
aggregation was increased in response to sub-
threshold doses of several agonists, such as ADP
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